| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
DSPE-PEG Carboxylic acid does not have a specific biological receptor target. The carboxylic acid group provides a reactive handle for conjugation to amine-containing molecules (e.g., proteins, peptides, targeting ligands) via EDC/NHS coupling chemistry.
|
|---|---|
| ln Vitro |
In vitro, DSPE-PEG Carboxylic acid sodium is used to form micelles as nanoparticles for drug delivery. The PEG-lipid can be utilized to prepare drug delivery nanoparticles and extends the blood circulation time of liposomes.
|
| ln Vivo |
In vivo, DSPE-PEG Carboxylic acid-containing formulations are used for drug delivery. The PEG component extends the blood circulation time of liposomes and nanoparticles. The carboxylic acid group enables conjugation of targeting ligands for active targeting applications.
|
| Enzyme Assay |
DSPE-PEG Carboxylic acid micelle formation involves dissolving the PEG-lipid in aqueous buffer above its critical micelle concentration. The carboxylic acid group can be activated with EDC/NHS to conjugate amine-containing targeting ligands or drugs. Micelle size and stability are characterized by dynamic light scattering.
|
| Cell Assay |
Cellular uptake and targeting efficacy of DSPE-PEG Carboxylic acid-based nanoparticles are assessed in cell culture. Nanoparticles conjugated to targeting ligands via the carboxylic acid group are added to cells, and uptake is quantified by fluorescence microscopy or flow cytometry. Drug delivery efficiency is measured by assessing the biological activity of encapsulated agents.
|
| Animal Protocol |
In vivo studies involve intravenous administration of DSPE-PEG Carboxylic acid-based formulations in rodent models. Pharmacokinetic parameters such as circulation half-life, tissue distribution, and therapeutic efficacy are evaluated. The PEG component extends circulation time, and targeting ligands can enhance accumulation at target sites.
|
| ADME/Pharmacokinetics |
DSPE-PEG Carboxylic acid sodium extends the blood circulation time of liposomes. The PEG component reduces opsonization and clearance by the mononuclear phagocyte system. The carboxylic acid group enables conjugation of targeting ligands. Pharmacokinetic properties depend on the formulation.
|
| Toxicity/Toxicokinetics |
DSPE-PEG Carboxylic acid sodium is generally considered biocompatible. The DSPE-PEG component has been used in pharmaceutical formulations. Standard safety precautions for handling PEGylated lipids should be followed. No significant toxicity has been reported.
|
| References | |
| Additional Infomation |
DSPE-PEG Carboxylic acid sodium (MW 2000, purity ≥98%) is a PEG-lipid that facilitates the formation of micelle nanoparticles for drug delivery and extends the blood circulation time of liposomes. The carboxylic acid group enables conjugation to targeting ligands or therapeutic agents, making it a valuable tool for drug delivery research.
|
| Molecular Formula |
(C2H4O)NC45H86NO12P.NA
|
|---|---|
| Molecular Weight |
2000(Average)
|
| Exact Mass |
2480.05
|
| CAS # |
1403744-37-5
|
| Appearance |
White to off-white solid powder
|
| SMILES |
[O-]C(=O)CO{-}CC{+n}OCC(=O)NCCOP(O)(=O)OCC(COC(CCCCCCCCCCCCCCCCC)=O)OC(=O)CCCCCCCCCCCCCCCCC.[Na+]
|
| InChi Key |
NIXOVWUDDMBODS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H34N4O5.C29H30N4O4.C29H30N2O3.C27H26N4O5.C25H21F3N4O4/c1-20(2)22-5-7-24(8-6-22)29(36)27-28(35(31(38)30(27)37)26-13-4-21(3)32-33-26)23-9-11-25(12-10-23)40-19-16-34-14-17-39-18-15-34;1-18-4-7-21(8-5-18)27(34)25-26(33(29(36)28(25)35)24-13-6-19(2)30-31-24)20-9-11-22(12-10-20)37-23-14-16-32(3)17-15-23;1-17(2)20-7-11-22(12-8-20)26-25(27(32)23-13-9-21(10-14-23)18(3)4)28(33)29(34)31(26)24-15-6-19(5)30-16-24;1-17-3-12-22(29-28-17)31-24(18-6-10-21(35-2)11-7-18)23(26(33)27(31)34)25(32)19-4-8-20(9-5-19)30-13-15-36-16-14-30;1-14-4-13-19(30-29-14)32-21(15-7-11-18(12-8-15)36-25(26,27)28)20(23(34)24(32)35)22(33)16-5-9-17(10-6-16)31(2)3/h4-13,20,28,36H,14-19H2,1-3H3;4-13,23,26,34H,14-17H2,1-3H3;6-18,26,32H,1-5H3;3-12,24,32H,13-16H2,1-2H3;4-13,21,33H,1-3H3
|
| Chemical Name |
4-[[4-(dimethylamino)phenyl]-hydroxymethylidene]-1-(6-methylpyridazin-3-yl)-5-[4-(trifluoromethoxy)phenyl]pyrrolidine-2,3-dione;4-[hydroxy-(4-methylphenyl)methylidene]-5-[4-(1-methylpiperidin-4-yl)oxyphenyl]-1-(6-methylpyridazin-3-yl)pyrrolidine-2,3-dione;4-[hydroxy-(4-morpholin-4-ylphenyl)methylidene]-5-(4-methoxyphenyl)-1-(6-methylpyridazin-3-yl)pyrrolidine-2,3-dione;4-[hydroxy-(4-propan-2-ylphenyl)methylidene]-1-(6-methylpyridazin-3-yl)-5-[4-(2-morpholin-4-ylethoxy)phenyl]pyrrolidine-2,3-dione;4-[hydroxy-(4-propan-2-ylphenyl)methylidene]-1-(6-methylpyridin-3-yl)-5-(4-propan-2-ylphenyl)pyrrolidine-2,3-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
THF: 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
